SPK001 monoclonal antibody: powerful broad-spectrum neutralization against SARS-CoV-2 variants of concern

SPK001, the monoclonal antibody developed by SpikImm, a biotech company founded by the Institut Pasteur and Truffle Capital, has demonstrated a potent and broad neutralization activity across all SARS-CoV-2 variants of concern, including omicron (BA.1 and BA.2). Originally developed in the Humoral Immunology lab headed by Dr Hugo Mouquet at the Institut Pasteur (joint research unit Inserm), SPK001 has also demonstrated in vivo prophylactic and therapeutic efficacies in mouse and hamster models. As most monoclonal antibodies commercially-available and in clinics partially or completely lost their effectiveness against omicron variants BA.1 and BA.2 (dominant worldwide since Dec 2021), SPK001 now appears as one of the most promising mAbs.

Results are available as preprint and have been submitted in an international peer-reviewed journal.

SpikImm expects to initiate clinical trials mi-2022.

Find out more